Related by context. All words. (Click for frequent words.) 76 Epidermal Growth Factor Receptor 76 Aurora Kinase 75 Protein Kinase C 75 Kinase Inhibitor 75 Receptor Antagonists 74 Receptor Agonist 74 Signaling Pathway 74 Recombinant Human 74 TNF Tumor Necrosis Factor 74 Glucocorticoid 74 Macrophage 74 pathophysiological effects 74 Factor Receptor 73 Cyclooxygenase 2 73 Monoclonal Antibody 73 Clusterin 73 interferon IFN 73 Tubulin 73 Receptor Antagonist 73 Prolongs Survival 73 Upregulation 73 Antitumor Activity 73 Anti Tumor 73 Transcription Factor 73 Interferon gamma 73 Dendritic Cells 73 Tumor necrosis factor 72 Immunomodulatory 72 Aliskiren 72 Novel Mechanism 72 Chemokine Receptor 72 TNF Blockers 72 Janus kinase 72 Bevacizumab 72 PEGylated anti 72 Anti Tumor Activity 72 Aptamer 72 Selective Inhibitor 72 Kinase Inhibitors 72 selectively inhibited 72 Topoisomerase II 72 Fibrinogen 72 protein tyrosine phosphatase 1B 72 Tyrosine Kinase Inhibitor 72 Cytotoxic 72 Hsp# Inhibitor 72 IGF1R 72 Cathepsin B 72 PKC# 72 Fibroblast 72 poly ADP ribose polymerase 72 hypoxia inducible factor 71 selective inhibition 71 Tumor Suppressor 71 Dasatinib 71 Orally Active 71 Angiotensin II 71 Catenin 71 Cytochrome P# 71 Pharmacokinetics PK 71 TNFalpha 71 Estrogen Receptor 71 selective modulator 71 Gleevec resistant 71 interleukin IL -# 71 Immune Responses 71 Antiangiogenic 71 thrombin receptor 71 adrenoceptor 71 Secretase 71 Allogeneic 71 Mouse Model 71 Phosphorylation 71 Enzastaurin 71 Adjuvant Chemotherapy 71 Gene Variants 71 Bortezomib 71 Androgen Receptor 71 JAK2 enzyme 71 Drug Candidate 71 Transdermal Delivery 71 FLT3 71 Factor VEGF 71 ACE Inhibitors 71 VEGF receptor 71 chemokine receptor 71 chimeric monoclonal antibody 71 Angiotensin Converting Enzyme 71 Diabetic Neuropathy 71 Cannabinoid 71 Kinoid 71 adrenoreceptor 71 Sapacitabine 71 Oncogenic 70 Decitabine 70 PDGFR 70 Epithelial 70 1 Antitrypsin 70 Previously Treated 70 PEGylated Fab fragment 70 Reductase 70 Tumour Necrosis Factor 70 Epratuzumab 70 VEGF inhibitors 70 Meets Primary Endpoint 70 Present Preclinical Data 70 androgen receptor AR 70 Breast Cancer Cells 70 proteasome inhibitors 70 Relapsed Refractory 70 TNF Alpha 70 Hypoxia Inducible Factor 70 5 HT6 receptor 70 Dehydrogenase 70 Presents Preclinical Data 70 HDACi 70 Myelofibrosis 70 alpha TNFa 70 erlotinib Tarceva ® 70 Interferon Beta 70 Monoclonal 70 Vidaza azacitidine 70 adalimumab Humira 70 adrenergic receptors 70 soluble tumor necrosis 70 hypereosinophilic syndrome 70 Nilotinib 70 cell adhesion molecule 70 selective agonist 70 Improves Survival 70 Enzyme Replacement Therapy 70 Kinase 70 selective antagonist 70 Modulates 70 vWF 70 Antitumor 70 Paraplatin ® 70 CYP#A# CYP#D# 70 TNF α 70 antisense oligonucleotide 70 Janus Kinase 70 Pertuzumab 70 Denufosol 70 Platelet Derived Growth 70 sodium glucose cotransporter 70 MTP inhibitor 70 phosphatidylinositol 3 70 1 antitrypsin 70 IL 1ß 70 Bosutinib 70 Glucocorticoids 70 Interferons 70 Allergic Rhinitis 70 alpha1 proteinase inhibitor 70 Orally administered 69 Monocytes 69 Cytotoxic T 69 receptor tyrosine kinase 69 thalidomide Thalomid 69 Blinatumomab 69 mineralocorticoid receptor 69 CYT# potent vascular disrupting 69 AT1R 69 related apoptosis inducing 69 dasatinib Sprycel 69 Maribavir 69 Hypercholesterolemia 69 beta1 69 serine protease 69 Polymerase Inhibitor 69 TNFα 69 receptor tyrosine kinase inhibitor 69 Tumor Targeting 69 Inhibits 69 vinca alkaloid 69 Protein Kinase 69 Malignant Glioma 69 Angiotensin 69 myelofibrosis polycythemia vera 69 Preclinical Data 69 Phase 2b Clinical Trial 69 Histone 69 Myelodysplastic Syndrome MDS 69 Mutational 69 Leukemias 69 IGFBP 3 69 Well Tolerated 69 Oral Fingolimod 69 GW# [003] 69 Disease Progression 69 mTOR mammalian target 69 retinoic acid receptor 69 Histone Deacetylase 69 Shows Promise Against 69 mitogen activated protein kinase 69 Granulocyte Colony Stimulating Factor 69 Cancer Cells 69 Muscarinic 69 Phase 2a Clinical Trial 69 Humanized Anti 69 Lymphocytic 69 Lenalidomide 69 Integrin 69 Omacetaxine 69 Retinoic Acid 69 Polymorphisms 69 Mg Usa 69 2A receptor agonist 69 Angiogenic 69 Cell Proliferation 69 chronic eosinophilic leukemia 69 immunostimulatory 69 SGLT2 69 Akt activation 69 beta3 69 elastase 69 5 lipoxygenase 69 histone deacetylase inhibitor 69 N methyl 69 SIRT2 69 HIF 1a 69 Novel Inhibitor 69 cortisol synthesis 69 small molecule tyrosine 69 Diabetic Nephropathy 69 Aldosterone 69 5 Fluorouracil 69 oral prodrug 69 Phase 2b Trial 69 Apoptotic 69 effector function 69 Autoantibodies 69 Assay Kits 69 Peginterferon 69 pDCs 69 Gene Mutation 69 Endothelial Cells 69 Erlotinib 69 sphingosine 1 69 Dapagliflozin 69 PI3K Akt 69 Anticancer Drugs 69 Antigen Specific 69 T#I [002] 69 Vascular Endothelial Growth 69 p# mitogen activated 69 receptor blocker 69 PI3K/mTOR 69 dasatinib Sprycel ® 69 EGFr 69 humanized monoclonal 69 Analogs 69 antisense inhibition 69 Hematopoietic 69 Tyrosine Kinase 69 1beta 69 mediated apoptosis 69 adipogenic 69 IL #R 69 irreversible inhibitor 69 Aurora kinase 69 proteasome inhibitor 69 DNA intercalator 68 Therapeutic Antibody 68 ligand TRAIL 68 Immunotherapeutic 68 Treatment Reduces 68 activin 68 Inhaled Corticosteroids 68 Adenosine 68 Lymphoid 68 HER1 68 LPA1 68 Voreloxin 68 calcitonin gene related 68 Hepatocellular 68 Monotherapy 68 imatinib Gleevec ® 68 Novel Oral 68 Preclinical Study 68 LPS induced 68 Small Molecule 68 Demonstrates Efficacy 68 Insulin Resistance 68 CYP#A# substrate 68 liposomal formulation 68 Nucleoside 68 antiapoptotic 68 pan HDAC inhibitor 68 Antiviral Activity 68 inverse agonist 68 Proteasome 68 TNF á 68 Inhibitor 68 PLA2 68 CCL# 68 Transgenic Mice 68 IGFBP2 68 Safinamide 68 Î ² 68 Systemic Delivery 68 Prodrug 68 beta adrenergic 68 Leukotriene 68 TNFa 68 ERK1 2 68 RNAi Therapeutic 68 pDC 68 See CLINICAL PHARMACOLOGY 68 antisense inhibitor 68 Rigel R# 68 Androgen 68 apoptosis inducing 68 Cytotoxicity 68 extracellular signal 68 HDAC Inhibitor 68 von Willebrand Factor 68 MEK ERK 68 potent cytotoxic 68 Fluorouracil 68 alpha1 68 Signaling Pathways 68 Progenitor Cells 68 Mucosal 68 IL6 68 Irinotecan 68 inducible nitric oxide synthase 68 cytokine signaling 68 tyrosine kinase 68 mGluR5 antagonist 68 Beta Amyloid 68 anti CD3 68 Phase 2a Trial 68 CDDO Im 68 Epstein Barr Virus EBV 68 AnaSpec Introduces 68 interleukin IL 68 Smooth Muscle 68 eotaxin 68 Kinases 68 Preclinical Models 68 downregulates 68 Anthracycline 68 cytostatic 68 CD4 + CD# 68 Induces 68 Therapeutic Efficacy 68 beta 1a 68 Differentially 68 PI3 Kinase 68 Advanced Renal Cell 68 phosphoprotein 68 K ras mutations 68 Secondary Hyperparathyroidism 68 MDR1 68 DFMO 68 TGF ß 68 Bavituximab 68 Transcriptional 68 laropiprant 68 TRAIL induced apoptosis 68 endoplasmic reticulum stress 68 Patients Receiving 68 Antithrombin 68 somatostatin analogue 68 arginine vasopressin AVP 68 Myeloid 68 Fungal Infections 68 Darapladib 68 Adenosine A2A 68 antimitotic 68 metastatic malignant 68 receptor agonists 68 Diffuse Large B 68 IAP inhibitor 68 Suppresses 68 Azacitidine 68 Hormone Refractory Prostate Cancer 68 Phospholipase A2 68 Allosteric 68 ara C 68 Chronic Myelogenous Leukemia 68 mGluR2 NAM 68 antibody MAb 68 reversible inhibitors 68 lysyl oxidase 68 Synthase 68 Demonstrates Potent 68 ERK pathway 68 immunotoxin 68 Mouse Models 68 Immunoglobulin 68 Adenoviral 68 Pulmonary Arterial Hypertension 68 Parathyroid Hormone 68 prostaglandin E2 PGE2 68 Epoetin 68 immune modulatory 68 Pegylated 68 Glycoprotein 68 Cardiotoxicity 68 Fludarabine 68 annexin V 68 intratumoral injection 68 thromboxane A2 68 mineralocorticoid 68 Mimetics 68 FGFR1 68 monocytes macrophages 68 CCR2 68 Factor VIIa 68 Single Dose 68 Flt3 68 triiodothyronine 68 uricase 68 NF kappaB activation 68 CXCL# 68 leukemia AML 68 VAPRISOL 68 HDAC2 68 Interferon Gamma 68 targeted radiotherapeutic 68 Plasmid DNA 68 cyclooxygenase COX 68 Trastuzumab 68 FasL 68 Complicated Skin 68 Glycosylation 68 Adjuvant Treatment 68 polyglutamate 68 Therapeutic Potential 68 Adrenergic 67 phosphorylates 67 NQO1 67 Elotuzumab 67 Myelodysplastic Syndromes 67 TRAIL receptors 67 selectively binds 67 Calcineurin 67 nucleoside analog 67 E selectin 67 Long Term Efficacy 67 Cholesterol Lowering Drug 67 Patients Treated With 67 investigational humanized monoclonal antibody 67 Etanercept 67 Incretin 67 5 HT2A serotonin 67 lysophosphatidic acid 67 Inhibitors 67 5 HT1A 67 Inactivation 67 antiproliferative effects 67 Dystrophin 67 methyl D aspartate 67 Newly Diagnosed 67 M1 muscarinic 67 Synuclein 67 tyrosine kinase receptor 67 Investigational Treatment 67 Fibroblast Growth Factor 67 Diabetic Neuropathic Pain 67 Th1 type 67 amikacin 67 Anthrax Toxin 67 Drug Shows Promise 67 fosbretabulin 67 thyroid hormone receptor 67 Induces Apoptosis 67 G Protein Coupled 67 Cutaneous T 67 leukocyte adhesion 67 Interferon alpha 67 secretase 67 Intracellular 67 tubulin polymerization 67 MUC1 67 Tumor Growth 67 alpha TNF 67 Cell Adhesion 67 myeloid derived 67 Inflammatory Markers 67 Interferon Alfa 67 cholesteryl ester transfer 67 TIMP 1 67 VEGFR1 67 Fulvestrant 67 Overexpression 67 Rheumatoid Arthritis Patients 67 Pemetrexed 67 Oral Mucositis 67 Oral Formulation 67 downstream effector 67 Receives Orphan Drug Designation 67 MTHFR 67 Malignant Melanoma 67 chemokine receptors 67 Antisense Drug 67 LAB CGRP 67 Protease Inhibitor 67 GSTP1 67 mitochondrial toxicity 67 Antisense Oligonucleotides 67 IFN α 67 Histamine 67 reversible inhibitor 67 Alkaline Phosphatase 67 5 HT4 67 Caveolin 1 67 ERK signaling 67 R lenalidomide 67 erythropoietic 67 1 antitrypsin AAT 67 thyrotropin 67 receptor modulators 67 Pharmacokinetic Study 67 Romidepsin 67 C5aR 67 matrix metalloproteases 67 PEG IFN 67 SAR# [002] 67 apoptosis proteins 67 nicotinic acetylcholine receptor 67 Fc fusion protein 67 Potent Anti 67 Skeletal Muscle 67 bleomycin 67 selectively inhibits 67 adenosine A2A 67 telomerase reverse transcriptase 67 Metabolites 67 Inhibitory 67 Temsirolimus 67 Superoxide 67 Virus Infection 67 downregulation 67 orally administered inhibitor 67 potent inducer 67 Fluticasone 67 HDAC enzymes 67 avidin 67 Degarelix 67 Chronic Myeloid Leukemia 67 Demonstrates Potential 67 topoisomerase II inhibitor 67 Anticancer Activity 67 c MET 67 GHRH 67 vinca alkaloids 67 cytochrome p# 67 histone deacetylase inhibitors 67 Genetic Variation 67 tumor antigen 67 Fingolimod 67 Naive Patients 67 Transmembrane 67 Study Evaluating 67 Cyclophosphamide 67 alpha GAL 67 agonist LABA 67 cytoprotective 67 Combination Treatment 67 Slows Progression 67 Protease Inhibitors 67 T#M 67 Albuferon TM 67 developing Bicifadine serotonin 67 JAK2 Inhibitor 67 FBPase 67 ERBB2 67 GPIIb IIIa 67 Replacement Therapy 67 Improves Outcomes 67 Clinical Trial Results 67 factor HGF 67 humanized anti 67 monocyte chemotactic protein 67 Pathway Inhibitor 67 Soft Tissue Sarcoma 67 anti angiogenic agent 67 immune modulating 67 Atypical Antipsychotic 67 receptor monoclonal antibody 67 IMiDs R 67 Autoimmune Disease 67 serine threonine kinase 67 peptide CGRP 67 IL 1β 67 dopamine D2 67 antifibrotic 67 ACC2 67 1 Proteinase Inhibitor 67 receptor CXCR4 67 Respiratory Virus 67 peptidic compound 67 CD#L 67 IGF 1R 67 antisense inhibitors 67 phosphate S1P 67 COX2 67 adenosine diphosphate ADP 67 Dose Response 67 peroxisome proliferator activated 67 alkylating agent 67 nucleoside analogues 67 Refractory Hodgkin Lymphoma 67 Thiazolidinediones 67 IFN beta 67 serotonin receptor 67 myeloproliferative diseases 67 Pegylated Interferon 67 Myeloma Patients 67 Transdermal Patch 67 antiproliferative activity 67 Reactive Oxygen Species 67 selective kinase inhibitor 67 potent anti angiogenic 67 Metastatic Prostate Cancer 67 mediated inhibition 67 depsipeptide 67 antineoplastic 67 adhesion molecule 67 Anti TNF 67 HCV protease 67 selectively inhibit 67 vascular disrupting agents 67 BCR ABL 67 Phase 2b Study 67 familial amyloidotic polyneuropathy FAP 67 Neutrophil 67 TNF receptor 67 receptor PPAR 67 epithelial tumors 67 Levels Linked 67 TGF alpha 67 targeted antifolate 67 Vidofludimus 67 Vidaza ® 67 endothelin receptor 67 Leukotrienes 67 Chemotherapy Induced 67 Initiates Clinical 67 cyclin dependent kinase inhibitor 67 Cytarabine 67 E#F# 67 IMiDs ® 66 Peginterferon Alfa 2a 66 cMET 66 protein kinase C 66 angiotensin receptor 66 HER2 receptor 66 heme oxygenase 1 66 Clinical Outcome 66 Completes Patient Enrollment 66 interferon γ 66 potent antiproliferative 66 generation antisense inhibitor 66 paclitaxel Taxol 66 Fondaparinux 66 FK# 66 Imatinib mesylate 66 kappa B 66 muscarinic 66 apoptotic pathway 66 Hepatic Encephalopathy 66 Novel Therapeutic 66 hepatoma 66 triggers apoptosis 66 glycogen synthase kinase 66 Epidermal Growth Factor 66 Xanafide 66 IGF IR 66 peptibody 66 erlotinib Tarceva 66 heparanase 66 Carcinomas 66 fibrin deposition 66 methionine aminopeptidase 66 LRP5 66 Notch receptor 66 PDE4 66 1α 66 mTOR inhibitors 66 Treatment Naïve 66 Eltrombopag 66 anionic backbone 66 FGFR4 66 Renal Cell Carcinoma 66 cyclic nucleotide 66 Uric Acid 66 PI3K/Akt pathway 66 endothelin receptor antagonists 66 Gefitinib 66 proapoptotic 66 Pralatrexate 66 CTLA 4 66 Th2 cytokines 66 cyclin dependent kinase 66 Inflammatory Pain 66 Severe Sepsis 66 inhibitor COX 66 Sphingomab 66 factor TNF 66 Monocyte 66 Angiotensin converting enzyme 66 Protein Linked 66 Genetic Mutation 66 Septic Shock 66 Hypertensive Patients 66 Aflibercept 66 IFNg 66 dihydrofolate reductase 66 MEK inhibitor 66 cyclin E 66 orally bioavailable 66 Natalizumab 66 induced apoptosis 66 Treatment Regimen 66 Shows Efficacy 66 Mesenchymal 66 HIF 1alpha 66 erythropoiesis 66 Combo Therapy 66 Zorbtive TM 66 Antifungal 66 IgG1 monoclonal antibody 66 Investigational Agent 66 accumulate preferentially 66 Anticancer Agent 66 Tiotropium 66 colorectal carcinoma 66 Diabetic Foot Ulcer 66 insulin sensitizers 66 Survival Benefit 66 integrin alpha 66 cyclooxygenase 2 66 mitogenic 66 Anti angiogenic 66 multikinase inhibitor 66 Dose Escalation Study 66 CXCR2 66 potently inhibit 66 Endotoxin 66 soluble receptor 66 NF kB pathway 66 Bone Morphogenetic Protein 66 naturally occurring molecule 66 LHRH 66 Ganciclovir 66 C Reactive Protein 66 ADP receptor antagonist 66 NKG2D 66 gastrin 66 binds selectively 66 induces apoptosis 66 LDL receptor 66 Mitoxantrone 66 TGF Beta 66 Attenuates 66 Carcinoid tumors 66 gamma secretase inhibitor 66 prostanoid 66 melanocyte stimulating hormone 66 Oncolytic 66 KRAS oncogene 66 Peginterferon alfa 2b 66 alpha folate receptor 66 Bucindolol 66 JAK2 V#F 66 Long acting beta2 66 tryptase 66 HLA DR4 66 Anti Angiogenic 66 Amyloid beta 66 glutamyl 66 EGFR tyrosine kinase inhibitors 66 BRAF V#E 66 Conjugate 66 Chronic Lymphocytic Leukemia CLL 66 NS#/#A protease 66 Sipuleucel T 66 R Saizen R 66 Deforolimus 66 microglial activation 66 Melphalan 66 receptor antagonism 66 Glufosfamide 66 Romiplostim 66 prostaglandin synthesis 66 Mg Uk 66 Talabostat 66 Demonstrated Significant 66 FDA Okays 66 tyrosine kinase inhibitors TKIs 66 PDGF receptor 66 c MYC 66 Heterozygous 66 Corticosteroids 66 Camptothecin 66 Hemophilia B 66 CD# CD# 66 alpha#beta# integrin 66 histone deacetylases 66 Aviptadil 66 Activating mutations 66 #HT#A 66 Galectin 66 heme oxygenase 66 leukotriene 66 Cytokines 66 histone deacetylase HDAC inhibitor 66 Sym# 66 Phosphodiesterase 66 benzimidazole 66 receptor subtype 66 Capecitabine 66 Ofatumumab 66 MMP2 66 WT1 66 Antiviral Therapy 66 PI3 kinase 66 Tyrosine 66 VEGFR2 66 myelodysplastic myeloproliferative diseases 66 tumor suppressor protein 66 Novel Compound 66 deacetylation 66 Peroxisome Proliferator Activated Receptor 66 receptor antagonists 66 Iloperidone 66 Lung Cancers 66 transthyretin 66 proto oncogene 66 demonstrated antitumor activity 66 potently inhibited 66 Chemotherapeutic 66 gonadotropin releasing hormone GnRH 66 NAGS deficiency 66 Bruton tyrosine kinase 66 IL 1Ra 66 Ischemic 66 Idiopathic Pulmonary Fibrosis 66 MGd 66 5 HT2A inverse 66 denileukin diftitox 66 constitutively activated 66 SPRYCEL ® 66 erythematosus 66 Extracellular 66 LPA1 receptor 66 Potent Inhibitor 66 γ secretase 66 histone deacetylase HDAC 66 Benign Prostatic Hyperplasia 66 gefitinib Iressa 66 cisplatin resistant 66 Tezampanel 66 CagA 66 busulfan 66 Darinaparsin 66 Pioglitazone 66 Thyroid Hormone 66 Sulfonylurea 66 TRAIL R2 66 trans retinoic acid 66 phosphoinositide 66 rhIL 7 66 kallikrein 66 Elvitegravir 66 EphB4 66 myeloperoxidase 66 Metastatic Renal Cell Carcinoma 66 microtubule targeting 66 Immunohistochemical analysis 66 Vorinostat 66 Therapeutic Vaccine 66 novel immunomodulatory 66 IgG1 antibody 66 Subunit 66 vimentin 66 Sevelamer 66 pharmacokinetic interactions 66 Previously Untreated 66 Silodosin 66 ErbB 66 Unfractionated Heparin 66 Cardiomyocytes 66 Imatinib 66 humanized antibody 66 HER2/neu 66 potent inhibition 66 Liposomal 66 V#F mutation 66 Inflammatory Diseases 66 prostaglandin D2 66 Endothelial 66 ptau 66 PTP 1B 66 Lung Cancer Drug 66 Fibrates 66 TNF alpha selectively neutralizing 66 2 methoxyestradiol 66 Chronic Lymphocytic Leukemia 66 NKX#.# 66 Philadelphia Chromosome Positive 66 D aspartate NMDA receptor 66 matrix metalloproteinases 66 DNA methyltransferase inhibitors 66 IND Application 66 Achieves Primary Endpoint 66 Interferon Alpha 66 pertussis toxin 66 replicon 66 Golimumab 66 Fracture Risk 66 Lupus Nephritis 66 Bicalutamide 66 Seliciclib 66 EZN 66 HCV polymerase 66 HER2 overexpression 66 Rho kinase 66 luteinizing hormone releasing 66 Myelodysplastic Syndrome 66 histone deacetylase 66 EGFR tyrosine kinase inhibitor 66 LRAT 66 vapreotide acetate 66 Adalimumab 66 MAP kinase 66 Randomized Phase 66 interferon gamma 66 Methylnaltrexone 66 Vaprisol 66 novel peptide 66 bortezomib Velcade 66 Aß 66 Vicriviroc 66 pyrimidines 66 cyclooxygenase 66 5 HT1A receptor 66 protein tyrosine phosphatase 66 Luteinizing Hormone Releasing Hormone 66 JAK Inhibitor 66 miR #a [002] 66 alpha#beta# 66 INTEGRILIN R 66 Remission Maintenance 66 bFGF 66 chitinase 66 NFkB 66 Interferon alfa 66 Ocrelizumab 66 colony stimulating factor 66 adipokine 65 humanised antibody 65 metaglidasen 65 Gout Drug 65 adenosine receptor 65 estramustine 65 targeting CD# 65 Combination Therapy 65 c KIT 65 sunitinib Sutent ® 65 isoproterenol 65 PPARgamma 65 humanised monoclonal antibody 65 III EGFRvIII 65 acetonide FA 65 alkylating 65 cytidine 65 endogenous ligands 65 Files IND 65 Interferon beta 1a 65 substrates inhibitors 65 alefacept 65 metalloproteinase 65 Is Well Tolerated 65 imatinib Gleevec 65 hydrolase 65 Blood Pressure Drug 65 Inflammatory Disease 65 TLR9 agonist 65 Gene Variant 65 TNF alpha antagonist 65 Phase IIb Trial 65 agonists antagonists 65 PDE4 inhibitor 65 ERalpha 65 Drug Resistant 65 HIF 1α 65 Fibrosis 65 iNOS 65 plasminogen activator inhibitor 65 Statistically Significant 65 receptor inhibitor 65 Aeolus Pharmaceuticals Announces 65 Panzem R 65 Fas ligand